Company profile: Trevi Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapies for uremic pruritus and chronic cough, including Haduvio—an investigational oral nalbuphine ER therapy targeting the central and peripheral nervous systems for idiopathic pulmonary fibrosis (IPF)-related cough and refractory chronic cough (RCC).
Products and services
- Haduvio (nalbuphine ER) for Idiopathic Pulmonary Fibrosis Chronic Cough: Oral, extended-release therapy that targets both central and peripheral nervous systems to treat chronic cough associated with idiopathic pulmonary fibrosis
- Haduvio (nalbuphine ER) for Refractory Chronic Cough: Oral, extended-release therapy targeting central and peripheral nervous systems to treat refractory chronic cough (RCC) by acting on both central and peripheral pathways
- Uremic Pruritus Drug Development: Clinical-stage biopharmaceutical programs that create therapeutics for treating uremic pruritus, focusing on developing drugs to address this condition.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Trevi Therapeutics
Noven Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty prescription pharmaceutical products, engaged in the research, development, manufacture, marketing and sale of these products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Noven Pharmaceuticals company profile →
Kymab
HQ: United Kingdom
Website
- Description: Provider of fully human monoclonal antibody therapeutics focused on immune-mediated diseases and immuno-oncology, developed using proprietary, integrated IntelliSelect platforms. IntelliSelect Transgenic platforms contain a full diversity of human antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kymab company profile →
Innate Pharma
HQ: France
Website
- Description: Provider of first-in-class immunotherapy drug candidates for cancer and inflammatory diseases, specializing in novel monoclonal antibodies and NK cell engagers targeting innate immunity pathways. Pipeline includes ANKET; Lacutamab for cutaneous and peripheral T cell lymphomas; Monalizumab (anti-NKG2A) and CD39 with AstraZeneca for NSCLC and other solid tumors; CD123 and B7-H3 multi-specific ANKETs with Sanofi.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Innate Pharma company profile →
4P Therapeutics
HQ: United States
Website
- Description: Provider of research and development of novel drug delivery technologies and therapeutics, developing pharmaceutical products from pre-clinical testing to clinical manufacturing, with a focus on meeting the needs of patients, physicians and payers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4P Therapeutics company profile →
Biovail
HQ: Canada
Website
- Description: Provider of pharmaceuticals as a Canadian pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biovail company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Trevi Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Trevi Therapeutics
2.2 - Growth funds investing in similar companies to Trevi Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Trevi Therapeutics
4.2 - Public trading comparable groups for Trevi Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →